Literature DB >> 18396207

Immunoglobulin allotypes influence IgG antibody responses to hepatitis C virus envelope proteins E1 and E2.

Janardan P Pandey1, Yuqun Luo, Robert C Elston, Yuping Wu, Frances Hite Philp, Jacquie Astemborski, David L Thomas, Dale M Netski.   

Abstract

Immunoglobulin (Ig) GM and KM allotypes-genetic markers of gamma and kappa chains, respectively-are associated with the outcome of hepatitis C virus (HCV) infection, but the underlying mechanisms are not well understood. We hypothesized that GM and KM allotypes could contribute to the outcome of HCV infection by influencing the levels of IgG antibodies to the HCV glycoproteins E1E2. We serologically allotyped 100 African American individuals with persistent HCV infection for GM and KM markers and measured anti-E1E2 antibodies. Subjects with the GM 1,17 5,13 phenotype had significantly higher levels of anti-E1E2 antibodies than subjects who lacked this phenotype (p = 0.008). Likewise, subjects with the KM 1-carrying phenotypes had higher levels of anti-E1E2 antibodies than subjects who lacked these phenotypes (p = 0.041). Median titers were fourfold higher in persons expressing both GM 1,17 5,13 and KM 1-carrying phenotypes compared with those who lacked these phenotypes (p = 0.011). Interactive effects of these GM-KM phenotypes were previously found to be highly significantly associated with spontaneous HCV clearance. Results presented here show that Ig allotypes contribute to the interindividual differences in humoral immunity to the HCV epitopes, a finding that may provide a mechanistic explanation for their involvement in the outcome of HCV infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18396207      PMCID: PMC2364665          DOI: 10.1016/j.humimm.2008.01.019

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  47 in total

1.  Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.

Authors:  B Stockmeyer; T Valerius; R Repp; I A Heijnen; H J Bühring; Y M Deo; J R Kalden; M Gramatzki; J G van de Winkel
Journal:  Cancer Res       Date:  1997-02-15       Impact factor: 12.701

2.  Limited humoral immunity in hepatitis C virus infection.

Authors:  M Chen; M Sällberg; A Sönnerborg; O Weiland; L Mattsson; L Jin; A Birkett; D Peterson; D R Milich
Journal:  Gastroenterology       Date:  1999-01       Impact factor: 22.682

3.  Variable domain-identical antibodies exhibit IgG subclass-related differences in affinity and kinetic constants as determined by surface plasmon resonance.

Authors:  L J Cooper; D Robertson; R Granzow; N S Greenspan
Journal:  Mol Immunol       Date:  1994-06       Impact factor: 4.407

Review 4.  IgG receptor polymorphisms: risk factors for disease.

Authors:  W van der Pol; J G van de Winkel
Journal:  Immunogenetics       Date:  1998-08       Impact factor: 2.846

5.  Can immunoglobulin C(H)1 constant region domain modulate antigen binding affinity of antibodies?

Authors:  O Pritsch; G Hudry-Clergeon; M Buckle; Y Petillot; J P Bouvet; J Gagnon; G Dighiero
Journal:  J Clin Invest       Date:  1996-11-15       Impact factor: 14.808

6.  Only selected light chains combine with a given heavy chain to confer specificity for a model glycopeptide antigen.

Authors:  M Czerwinski; D Siemaszko; D L Siegel; S L Spitalnik
Journal:  J Immunol       Date:  1998-05-01       Impact factor: 5.422

Review 7.  Advances in human immunoglobulin allotypes.

Authors:  R Grubb
Journal:  Exp Clin Immunogenet       Date:  1995

8.  Immunoglobulin mimicry by Hepatitis C Virus envelope protein E2.

Authors:  Yu-Wen Hu; Lynda Rocheleau; Bryce Larke; Linda Chui; Bonita Lee; Mang Ma; Song Liu; Teye Omlin; Martin Pelchat; Earl G Brown
Journal:  Virology       Date:  2005-02-20       Impact factor: 3.616

9.  Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy.

Authors:  S C Ray; Y M Wang; O Laeyendecker; J R Ticehurst; S A Villano; D L Thomas
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

10.  Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients.

Authors:  J C Booth; U Kumar; D Webster; J Monjardino; H C Thomas
Journal:  Hepatology       Date:  1998-01       Impact factor: 17.425

View more
  11 in total

1.  Immunoglobulin locus associates with serum IgG levels and albuminuria.

Authors:  Stacy M Herring; Nisha Gokul; Monique Monita; Rebecca Bell; Eric Boerwinkle; Scott E Wenderfer; Michael C Braun; Peter A Doris
Journal:  J Am Soc Nephrol       Date:  2011-03-31       Impact factor: 10.121

2.  Immunoglobulin genes and the acquisition of HIV infection in a randomized trial of recombinant adenovirus HIV vaccine.

Authors:  Janardan P Pandey; Aryan M Namboodiri; Shizhong Bu; Jean De Dieu Tapsoba; Alicia Sato; James Y Dai
Journal:  Virology       Date:  2013-04-11       Impact factor: 3.616

3.  Genetic markers of IgG influence the outcome of infection with hepatitis C virus.

Authors:  Janardan P Pandey; Aryan M Namboodiri; Yuqun Luo; Yuping Wu; Robert C Elston; David L Thomas; Hugo R Rosen; James J Goedert
Journal:  J Infect Dis       Date:  2008-11-01       Impact factor: 5.226

4.  Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study.

Authors:  Geertje M Bartelds; Els de Groot; Michael T Nurmohamed; Margreet H L Hart; Peter H van Eede; Carla A Wijbrandts; Jakob B A Crusius; Ben A C Dijkmans; Paul Peter Tak; Lucien Aarden; Gerrit J Wolbink
Journal:  Arthritis Res Ther       Date:  2010-12-27       Impact factor: 5.156

5.  Immunoglobulin GM 3 23 5,13,14 phenotype is strongly associated with IgG1 antibody responses to Plasmodium vivax vaccine candidate antigens PvMSP1-19 and PvAMA-1.

Authors:  Janardan P Pandey; Cristiane G Morais; Cor Jf Fontes; Erika M Braga
Journal:  Malar J       Date:  2010-08-09       Impact factor: 2.979

6.  Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study.

Authors:  Ariana Montes; Eva Perez-Pampin; Federico Navarro-Sarabia; Virginia Moreira; Arturo Rodríguez de la Serna; Berta Magallares; Yiannis Vasilopoulos; Theologia Sarafidou; Antonio Fernández-Nebro; María Del Carmen Ordóñez; Javier Narváez; Juan D Cañete; Ana Marquez; Dora Pascual-Salcedo; Beatriz Joven; Patricia Carreira; Manuel J Moreno-Ramos; Rafael Caliz; Miguel Angel Ferrer; Rosa Garcia-Portales; Francisco J Blanco; Cesar Magro; Enrique Raya; Lara Valor; Juan J Alegre-Sancho; Alejandro Balsa; Javier Martin; Darren Plant; John Isaacs; Ann W Morgan; Anne Barton; Anthony G Wilson; Juan J Gómez-Reino; Antonio Gonzalez
Journal:  Arthritis Res Ther       Date:  2015-03-18       Impact factor: 5.156

7.  Immunoglobulin G1 Allotype Influences Antibody Subclass Distribution in Response to HIV gp140 Vaccination.

Authors:  Sven Kratochvil; Paul F McKay; Amy W Chung; Stephen J Kent; Jill Gilmour; Robin J Shattock
Journal:  Front Immunol       Date:  2017-12-20       Impact factor: 7.561

8.  FcγR Binding and ADCC Activity of Human IgG Allotypes.

Authors:  Steven W de Taeye; Arthur E H Bentlage; Mirjam M Mebius; Joyce I Meesters; Suzanne Lissenberg-Thunnissen; David Falck; Thomas Sénard; Nima Salehi; Manfred Wuhrer; Janine Schuurman; Aran F Labrijn; Theo Rispens; Gestur Vidarsson
Journal:  Front Immunol       Date:  2020-05-06       Impact factor: 7.561

9.  The forgotten tale of immunoglobulin allotypes in cancer risk and treatment.

Authors:  Janardan P Pandey; Zihai Li
Journal:  Exp Hematol Oncol       Date:  2013-02-20

Review 10.  Immunoglobulin GM Genes, Cytomegalovirus Immunoevasion, and the Risk of Glioma, Neuroblastoma, and Breast Cancer.

Authors:  Janardan P Pandey
Journal:  Front Oncol       Date:  2014-08-29       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.